Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Metastatic Solid Tumors 1Malignant Solid Tumor 1Gynecological Solid Tumors 1Advanced Solid Tumor Malignancies 1Advanced Solid Tumor 1

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Platinum 1Nivolumab 1Ipilimumab 1Iodine-125 1Gemcitabine 1FANG vaccine 1Electrocardiography 1Echocardiography 1DOXO-EMCH 1Cetuximab 1Cell- and Tissue-Based Therapy 1Antibodies, Bispecific 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Antibodies, Bispecific × Other solid neoplasm × Clear all
NCT00149019 2011-04-08

Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

Hadassah Medical Organization

Phase 2 Withdrawn
12 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡